Table 2.
Selected Inhibitors against Transcription Factors (TFs) in Clinical Trials.
| TFs | Therapeutics | Phase | Cancer Type | Status | Trial Identifier |
|---|---|---|---|---|---|
| STAT3 | OPB-31121 | Phase I | Advanced solid tumors | Completed | NCT00955812 |
| OPB-51602 | Phase I | Advanced cancers | Completed | NCT01423903 | |
| AZD9150 (IONIS-STAT3Rx) |
Phase I/II | Advanced cancers, Diffuse Large B Cell Lymphoma, Lymphoma | Completed | NCT01563302 | |
| WP1066 | Phase I | Metastatic malignant neoplasm in the brain, metastatic melanoma, recurrent brain neoplasm, recurrent glioblastoma, recurrent malignant glioma | Recruiting | NCT01904123 | |
| TTI-101 | Phase I | Breast cancer, head and neck squamous cell carcinoma, Non-small cell lung cancer (NSCLC), HCC, colorectal cancer, gastric adenocarcinoma, melanoma, advanced cancer | Recruiting | NCT03195699 | |
| NF-κB | Imx-110 | Phase I/II | Advanced solid tumors, pancreatic cancer, breast Cancer, ovarian cancer | Recruiting | NCT03382340 |
| BR-DIM | Phase I | Nonmetastatic hormone-refractory prostate cancer | Completed | NCT00305747 | |
| Curcumin | Phase II | Breast cancer | Completed | NCT01740323 | |
| HIF-1 | Digoxin | Phase II | Breast cancer | Completed | NCT01763931 |
| Topotecan | Phase I | Refractory advanced solid neoplasms expressing HIF-1α | Completed | NCT00117013 | |
| PX-478 | Phase I | Advanced solid tumors, lymphoma | Completed | NCT00522652 | |
| EZN-2208 | Phase I | Refractory solid tumors (in combination with Bevacizumab) | Completed | NCT01251926 | |
| CRLX101 | Phase II | Recurrent platinum-resistant ovarian cancer, Fallopian tube cancer, primary peritoneal cancer (in combination with Bevacizumab) | Completed | NCT01652079 | |
| RO7070179 | Phase I | Hepatocellular carcinoma | Completed | NCT02564614 | |
| Vorinostat | Phase I | Advanced Breast Cancer (in combination with Capecitabine) | Completed | NCT00719875 | |
| PT2385 | Phase I | Advanced clear cell renal cell carcinoma, kidney cancer (alone or in combination with nivolumab or cabozantinib) | Active | NCT02293980 | |
| Myc | BMS-986158 | Phase I | Pediatric solid tumors, lymphoma, or brain tumor | Recruiting | NCT03936465 |
| GSK525762 | Phase I/II | Relapsed, refractory hematological malignancies | Completed | NCT01943851 | |
| MLN8237 | Phase II | Histologically confirmed or clinically suspected metastatic neuroendocrine Prostate cancer | Completed | NCT01799278 | |
| RO6870810 | Phase I | Relapsed/refractory acute myeloid leukemia (AML) | Completed | NCT02308761 | |
| Wnt/Beta-catenin | PRI-724 | Phase I | Pancreatic adenocarcinoma, which is locally advanced, metastatic, or otherwise inoperable. These patients are candidates for second-line therapy after failing FOLFIRINOX as first-line therapy (in combination with gemcitabine) | Completed | NCT01764477 |
| CWP232291 | Phase I/II | Relapsed or refractory AML (in combination with Cytarabine) | Active | NCT03055286 | |
| Vantictumab | Phase I | Previously untreated stage IV pancreatic cancer (in combination with nab-paclitaxel and gemcitabine) | Completed | NCT02005315 | |
| Ipafricept (OMP-54F28) |
Phase I | Solid tumors | Completed | NCT01608867 | |
| Ipafricept (OMP-54F28) |
Phase I | Previously untreated stage IV pancreatic cancer (in combination with nab-paclitaxel and gemcitabine) | Completed | NCT02050178 | |
| Foxy-5 | Phase II | Resected colon cancer patients treated with FOLFOX chemotherapy regimen | Recruiting | NCT03883802 | |
| E2F | Ribociclib | Phase I | Recurrent Glioblastoma or anaplastic Glioma | Unknown | NCT02345824 |
| Palbociclib | Phase I/II | Advanced KRAS mutant NSCLC (in combination with MEK inhibitor Binimetinib) | Recruiting | NCT03170206 | |
| Abemaciclib | Phase II | Chemo-refractory, Rb wild-type extensive Small-cell lung cancer | Recruiting | NCT04010357 | |
| G1T38 | Phase I/II | EGRF mutation-positive metastatic NSCLC (in combination with Osimertinib) | Active | NCT03455829 |